Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. We studied the biological characteristics of these tumours by comparing the overexpression of oncogenes ERBB2, MYC, CCND1 and RHOC and TP53 gene mutation rates in IBC with those found in locally advanced and not otherwise specified breast cancers. The prevalence of the TP53 mutation was much higher in IBC than in the two other types of cancer (57% vs 30). Unexpectedly, however, in IBC tumours, histological grade was independent of TP53 status. In addition, ERBB2 overexpression was twice as frequent in inflammatory as in non-inflammatory tumours, whereas the frequencies of MYC, CCND1 and RHOC overexpression did not vary significantly among the three types of breast cancer. These findings suggest that IBC tumours constitute a distinct subset with a specific pathogenesis. Given the importance of TP53 and ERBB2 in the response to treatments, our observations have important therapeutic implications for the clinical management of IBC patients.
Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. We studied the biological characteristics of these tumours by comparing the overexpression of oncogenes ERBB2, MYC, CCND1 and RHOC and TP53 gene mutation rates in IBC with those found in locally advanced and not otherwise specified breast cancers. The prevalence of the TP53 mutation was much higher in IBC than in the two other types of cancer (57% vs 30). Unexpectedly, however, in IBC tumours, histological grade was independent of TP53 status. In addition, ERBB2 overexpression was twice as frequent in inflammatory as in non-inflammatory tumours, whereas the frequencies of MYC, CCND1 and RHOC overexpression did not vary significantly among the three types of breast cancer. These findings suggest that IBC tumours constitute a distinct subset with a specific pathogenesis. Given the importance of TP53 and ERBB2 in the response to treatments, our observations have important therapeutic implications for the clinical management of IBC patients. Oncogene (2002 Oncogene ( ) 21, 7593 -7597. doi:10.1038 Keywords: oncogene; amplification; quantitative PCR; therapy Inflammatory breast cancer (IBC), one of the most aggressive forms of localized breast cancer, accounts for up to 5% of malignant breast tumours. Whereas most IBC patients treated by surgical removal die less than 24 months after diagnosis, an approach combining chemotherapy, surgery, and radiation therapy has increased 5-year overall survival by up to 55% (Chang et al., 1998; Gradishar, 1996) . We studied the biological characteristics of this subset of tumours by comparing oncogene expression and TP53 mutation rates with those found in other types of breast cancer, namely, locally advanced breast cancer (LABC) and standard, not otherwise specified (NOS) tumours. We analysed the TP53 tumour suppressor gene whose modulation of cell cycle and apoptosis have been shown to play a critical role in the tumour response to both chemo-or radiation therapy and survival (Bertheau et al., 2002; Cuny et al., 2000; Degeorges et al., 1998; Seshadri et al., 1996) . We also monitored, by real-time polymerase chain reaction (PCR), the expression of four oncogenes which are involved in distinct biochemical pathways that control cell growth (ERBB2, MYC, CCND1) or metastasis formation (RHOC) whose expression is known to be altered in breast tumours (Clark et al., 2000; Scorilas et al., 1999; Sjo¨strom et al., 1998) .
In all, 161 patients were studied. They were divided into three groups: group 1 comprised 63 patients whose IBC was diagnosed and treated in the Hoˆpital SaintLouis between 1990 and 1998. IBC was diagnosed on clinical examination when patients presented with local oedema, redness of the skin and rapid tumour growth. These patients' median age was 48 years (28 -69). All their tumours were classified as T4d (UICC, 1997). Group 2 included 27 LABC patients (stages IIIA and IIIB) whose median age was 47 years (30 -69). Group 3 was a control group of 71 patients with NOS tumours (median age: 56 years (30 -84)). Pathological examination of surgical biopsies showed that in four out of 63 cases of IBC, two out of 27 of LABC and four out of 71 of NOS, tumours were lobular adenocarcinomas, and in all the remaining cases, of the ductal type. By modified Scarff, Bloom and Richardson grading (Elston, 1987) , 24 IBC tumours were classified as grade 2, 35 as grade 3 and one as grade 1. Twelve of the 27 LABC cases were grade 2, and 13, grade 3. Three IBC and 2 LABC cases could not be graded because of poor pathological material. Out of the 71 cases with NOS tumours, four were grade 1, 35 were grade 2, and 32, grade 3. Oestrogen and progesterone receptor status were determined by radiolabelled ligand binding assays. Twenty-two out of 44 IBC, 16 out of 27 LABC and 23 out of 63 NOS tumours were hormone-receptor negative, i.e. contained 510 fmol/mg protein. Tumour samples, snap-frozen less than 10 min after surgical removal, were obtained for RNA extraction at the time of diagnosis. Samples containing more than 70% tumour cells were considered suitable for the study. Tumour samples were either stored in liquid nitrogen until use, or were homogenized and RNAs were immediately isolated according to Chomczynski and Sacchi (1987) and stored at 7808C.
Analysis of the TP53 gene status in IBC and LABC tumours (Figure 1a ), showed that 36 out of 63 of IBC tumours (57%) and 10 out of 27 LABC tumours (37%) exhibited TP53 mutations. Therefore, although the prevalence of TP53 mutations in LABC was similar to that reported in NOS breast cancer, i.e. *30% (Bertheau et al., 2002; Coles et al., 1992; Saitoh et al., 1994; Turpin et al., 1999) , it was much higher in IBC. The well known association between a high histological grade and TP53 mutation (Degeorges et al., 1998; Sato et al., 1997; Silvestrini et al., 1996; Turpin et al., 1999; Valgardsdottir et al., 1997) was not found here in IBC (Figure 1b) . Indeed, in our patients, a significant number of TP53 mutant tumours were grade 2 ( Figure 1b ) and no significant correlation was found between the two parameters, in sharp contrast to LABC tumours. As expected, in the three subsets of breast cancer, TP53 WT tumours were mostly hormone-receptor positive, whereas TP53 MUT tumours were mostly hormonereceptor negative (not shown).
Oncogene mRNA expression could only be tested on 47 IBC and 10 LABC tumours due to restricted RNA sample availability. Oncogene overexpression ( Figure  2 ) was much greater for ERBB2 than for CCND1 (up to 64 times vs up to 19 times the basal level) or MYC and RHOC (up to 10 times the basal level). As previously, a threefold increase compared to normal breast tissue was considered overexpression (Bie`che et al., 1999b) . Seventeen out of 47 IBC tumours (36%) exhibited ERBB2 overexpression (Figure 2a ), 11 out of 47 (23%), MYC overexpression (Figure 2c) , and nine out of 47 (19%), CCND1 overexpression (Figure 2e) . RHOC was expressed in all IBC tumours, but was only overexpressed in three out of 32, (9.4%, Figure 2g ). Compared to a previous study in which TP53 status and RHOC overexpression were not determined (Bie`che et al., 1999b (Bie`che et al., , 2002 , we found a great increase in ERBB2 overexpression and a moderate increase in that of CCND1 in IBC tumours, but MYC overexpression did not change significantly.
In our small LABC population, the prevalences of ERBB2, MYC and CCND1 overexpression were close to those found in the IBC group (30 vs 36%, 30 vs 23% and 20 vs 19%, respectively), whereas RHOC overexpression was higher in LABC than in IBC or NOS (30 vs 9.4 and 16.6%, respectively, data not shown). Since in IBC both the presence of TP53 mutation and ERBB2 overexpression were very marked (although they were not correlated, Figure 3a ), we studied a control series of 71 NOS breast cancer cases for oncogene overexpression in 34 tumours bearing a TP53 mutation and 37 TP53 WT tumours. Nineteen out of 71 patients (26.8%), exhibited ERBB2 overexpression (Figure 2b ), 13 out of 71 (18.3%) MYC overexpression (Figure 2d ), 13 out of 71 (18%) CCND1 overexpression ( Figure 2f ) and seven out of 42 (16.6%) RHOC overexpression (Figure 2h ). Although CCND1 overexpression was similar in IBC and NOS, its amplitude was greater in IBC than in NOS (Figure 2e ,f, respectively). Note that TP53 MUT was clearly correlated with ERBB2 overexpression in NOS (Figure 3a ), but not with overexpression of CCND1, MYC or RHOC (not shown). On the other hand, MYC overexpression correlated closely with normal ERBB2 expression in IBC (Figure 3b ). In conclusion, we found that the TP53 mutation and ERBB2 overexpression were far more frequent in IBC, which might explain their greater clinical aggressiveness. Given the small population (Flaman et al., 1995; Waridel et al., 1997) . This test was reported to detect over 90% of the mutations identified. Correlations between biological factors were determined by Fishers' exact test TP53 mutations and ERBB2 overexpression in inflammatory breast cancer E Turpin et al Figure 2 Distribution of ERBB2, MYC, CCND1 and RHOC mRNA expression in patients with inflammatory breast cancer (IBC) and not otherwise specified (NOS) breast cancer. The oncogenes analysed and patients studied are indicated. Oncogene overexpression was determined by real-time quantitative RT -PCR assay, as previously described for ERBB2, MYC and CCND1 (Bie`che et al., 1999a,b, 2002) . RHOC expression was determined by real-time quantitative RT -PCR assay designed as follows: forward primer -5'-TCC TCA TCG TCT TCA GCA AG-3', reverse primer -5'-GAG GAT GAC ATC AGT GTC CG-3' (Suwa et al., 1998) and probe -5'-TAC GTC CCT ACT GTC TTT GAG AAC TAT AT-3'; 40 cycles at 958C for 15 s and 608C for 1 min. The TATA box-binding protein (TBP) gene was used as internal control and each sample was normalized on the basis of its TBP mRNA content, as previously described (Bie`che et al., 1999a,b, 2002)
TP53 mutations and ERBB2 overexpression in inflammatory breast cancer E Turpin et al studied, no attempts were made to correlate these molecular findings with survival. Very few studies have addressed the biological characteristics of IBC, probably because of the low incidence of this type of tumour (Garcia et al., 1989; Guerin et al., 1989; Vincent-Salomon et al., 2000) . Here, we demonstrated that (1) ERBB2 overexpression and the TP53 mutation are, as stated above, much more frequent in IBC than in other breast cancers, and that the histological grade is independent of TP53 status; (2) MYC and ERBB2 overexpression are almost mutually exclusive in IBC, and (3) in NOS breast cancer, ERBB2 overexpression is much more common among TP53 MUT tumours. Breast cancers are widely believed to constitute distinct molecular malignancies (Sainsbury et al., 2000) . Identification of these subjects would be extremely important to obtain molecular/ clinical correlates, as was recently suggested for colon cancer in a study of the response to 5-FU by patients with microsatellite instability (MSI) and non-MSI tumours (Bunz et al., 1999; Elsaleh et al., 2000) . Many authors have studied the prevalence of oncogene expression and its possible link with tumour evolution (Cuny et al., 2000; Guerin et al., 1988; Re´villion et al., 1998; Scorilas et al., 1999; Seshadri et al., 1996) . These studies have often been disappointing, perhaps because they only dealt with the expression of one or a few oncogenes in a heterogeneous group of tumours. Subsequently, the authors of several cDNA array studies defined a set of different breast tumours as being of the basal type, luminal type, ERBB2, etc. (Perou et al., 2000; Sorlie et al., 2001) and identified genes whose expression predisposes to metastatic evolution (van 't Veer et al., 2002) . Nevertheless, TP53 mutations were not determined in most studies, and IBC tumours were not analysed at all.
Here, we found a greatly increased prevalence of TP53 mutations in IBC, as in medullary breast cancers (de Cremoux et al., 1999) . It is very striking that, in inflammatory breast cancer tumours, unlike all the studies of non-inflammatory breast cancer tumours, we found no correlation between the presence of mutant TP53 and a high histological grade. In particular, the finding that a number of grade 2 tumours were mutated, suggests that in an inflammatory setting, loss of TP53 function does not have the same consequences for cell morphology and tissue architecture (Kerangueven et al., 1997) . Absence of TP53 function predisposes to genome instability, which may account for our finding of frequent ERBB2 overexpression in TP53 mutant NOS tumours, in agreement with the results of previous immunochemistry studies (Nakopoulou et al., 1996) and with the identification by RNA profiling of a distinct cluster of tumours exhibiting ERBB2 overexpression and TP53 mutations (Sorlie et al., 2001) . We also found that the presence of ERBB2 and MYC overexpressions were mutually exclusive, which is in agreement with the inverse correlation between the amplification of these genes (Garcia et al., 1989) . This might be consistent with the idea, either that MYC expression is downstream of ERBB2 activation (Huang et al., 2002) or that the signalling pathways of these two oncogenes need not be simultaneously activated. Lastly, we observed that RHOC overexpression, which was associated with metastatic tumour cells, was not more frequent in IBC than in NOS tumours, contrarily to a previous report (van Golen et al., 1999) .
On the clinical level, the high prevalence of ERBB2 overexpression and TP53 mutations, might account for the distinct biological features of these tumours (high growth rate, chemosensitivity and inflammation). We recently showed that in LABC, TP53 status is a major determinant of the histological response to chemotherapy (Bertheau et al., 2002) . Hence, the high prevalence of TP53 mutations in IBC is likely to be of clinical significance. In addition, since antibody therapy targeted to ERBB2 has been shown to be of clinical interest in numerous clinical trials (Cobleigh et al., 1999; Dillman, 1999; Stebbing et al., 2000) , the much higher prevalence of ERBB2 overexpression in our group of IBC patients than in the other groups suggests that they in particular could benefit from such therapy.
